Skip to content

CNS & Neurological Disorders - Drug Targets

ISSN 1871-5273

3 papers in the library · 62 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

From Molecules to Minds: Redefining the Power of Psychedelics and Entactogens in Treating Brain Disorders

CNS & Neurological Disorders - Drug Targets July 31, 2026 Sampriti Paul, Sonal Dubey, Mayur Yergeri Chandrasekharappa et al.

Recent advances in neuropsychopharmacology have renewed interest in psychedelics and entactogens as potential treatments for brain disorders, owing to their rapid effects on neural plasticity, cognition, and affect. Classical serotonergic psychedelics primarily act as 5-HT2A receptor agonists with additional activity at 5-HT1A and other serotonin receptors, whereas entactogens such as MDMA...

Zolpidem vs. Emerging Hypnotics: Neuropsychiatric Effects and Ethical Considerations

CNS & Neurological Disorders - Drug Targets July 16, 2026 Tawqeer Shafi, Zora Singh, Puja Gulati et al.

INTRODUCTION: Zolpidem is a widely used non-benzodiazepine hypnotic that is used as a treatment for insomnia due to its rapid onset and perceived safety. Nevertheless, rising clinical reports and post-marketing surveillance have identified serious neuropsychiatric adverse effects, such as hallucinations, perceptual disturbances, and complex sleep-related behaviors, such as sleep-driving and...

Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset

CNS & Neurological Disorders - Drug Targets April 17, 2017 Giovanni Martinotti, Rita Santacroce, Duccio Papanti et al. 62 citations

BACKGROUND: Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. The short- and long- term health risks associated with the consumption of SC are often unknown to both users and health professionals. This review aims to provide a synthesis of the most recent and relevant insights on the pharmacology, clinical and psychopathological aspects of SC....